Fulcrum Therapeutics (FULC.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec10

RA Capital Management Sells Fulcrum Therapeutics Common Stock

21:43

HC Wainwright Raises Fulcrum Therapeutics Earnings Estimate to $0.94 and Sets $25 Target Price

13:01

Fulcrum Therapeutics Expands Initial Public Offering

12:49

Oct29

Fulcrum Therapeutics released FY2025 Q3 earnings on October 29 Pre-Market (EST), actual revenue USD 0, actual EPS USD -0.313 (forecast EPS USD -0.29)

13:30

Fulcrum Therapeutics released FY2025 9 Months Earnings on October 29 Pre-Market EST, with actual revenue of USD 0 and EPS of USD -0.8756

13:30

Fulcrum Therapeutics Inc. Reports Positive Clinical Trial Results for Pociredir

11:24

Schedules & Filings

Schedules

Filings

Oct29

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -19.6 M, EPS -0.313

Jul29

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -17.3 M, EPS -0.28

May1

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -17.66 M, EPS -0.2825

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change